- Home
- GAME vs SCYX Comparison
GAME vs SCYX Comparison
Compare GAME & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- SCYX
- Stock Information
- Founded
- GAME 2011
- SCYX 1999
- Country
- GAME United States
- SCYX United States
- Employees
- GAME N/A
- SCYX N/A
- Industry
- GAME
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- SCYX Health Care
- Exchange
- GAME Nasdaq
- SCYX Nasdaq
- Market Cap
- GAME 27.2M
- SCYX 28.5M
- IPO Year
- GAME 2009
- SCYX 2014
- Fundamental
- Price
- GAME $1.66
- SCYX $0.82
- Analyst Decision
- GAME Strong Buy
- SCYX
- Analyst Count
- GAME 3
- SCYX 0
- Target Price
- GAME $3.67
- SCYX N/A
- AVG Volume (30 Days)
- GAME 8.2M
- SCYX 176.2K
- Earning Date
- GAME 08-13-2025
- SCYX 08-07-2025
- Dividend Yield
- GAME N/A
- SCYX N/A
- EPS Growth
- GAME N/A
- SCYX N/A
- EPS
- GAME N/A
- SCYX N/A
- Revenue
- GAME $99,579,536.00
- SCYX $2,630,000.00
- Revenue This Year
- GAME $6.08
- SCYX $463.61
- Revenue Next Year
- GAME $21.94
- SCYX $310.80
- P/E Ratio
- GAME N/A
- SCYX N/A
- Revenue Growth
- GAME 77.06
- SCYX N/A
- 52 Week Low
- GAME $0.50
- SCYX $0.66
- 52 Week High
- GAME $2.87
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- GAME 66.62
- SCYX 57.87
- Support Level
- GAME $1.67
- SCYX $0.67
- Resistance Level
- GAME $2.20
- SCYX $0.75
- Average True Range (ATR)
- GAME 0.27
- SCYX 0.04
- MACD
- GAME 0.11
- SCYX 0.01
- Stochastic Oscillator
- GAME 43.64
- SCYX 93.53
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.